4-methoxybenzylphosphonous acid | 326480-16-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 4-methoxybenzylphosphonous acid
• 英文别名: 4-methoxy-benzylphosphinic acid；[(4-methoxyphenyl)methyl]phosphinic acid；(4-Methoxyphenyl)methylphosphinic acid
• CAS: 326480-16-4
• 化学式: C₈H₁₁O₃P
• 分子量: 186.147
• InChiKey: ZZSLMWOFGYUIAF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  52.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-methoxybenzylphosphonous acid 在 sodium hydride 、 N,N'-二环己基碳二亚胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 18.0h， 生成 2-[Benzyloxy-(4-methoxy-benzyl)-phosphinoylmethyl]-pentanedioic acid dibenzyl ester
  参考文献：
  名称：

  Design and Pharmacological Activity of Phosphinic Acid Based NAALADase Inhibitors

  摘要：

  A novel series of phosphinic acid based inhibitors of the neuropeptidase NAALADase are described in this work. This series of compounds is the most potent series of inhibitors of the enzyme described to date. In addition, we have shown that these compounds are protective in animal models of neurodegeneration. Compound 34 significantly prevented neurodegeneration in a middle cerebral artery occlusion model of cerebral ischemia. In addition, in the chronic constrictive mc del of neuropathic pain, compound 34 significantly attenuated the hypersensitivity observed with saline-treated animals. These data suggest that NAALADase inhibition may provide a new approach for the treatment of both neurodegenerative disorders and peripheral neuropathies.

  DOI：

  10.1021/jm0001774
• 作为产物：
  描述：

  4-methoxybenzyl phosphine 在 氧气 作用下， 以 氯仿 为溶剂， 反应 2.0h， 以82%的产率得到4-methoxybenzylphosphonous acid
  参考文献：
  名称：

  摘要：

  4-Methoxybenzyl chloride reacts with elemental (red or white) phosphorus under the conditions of phase-transfer catalysis (concentrated aqueous KOH, dioxane, benzyltriethylammonium chloride, 85-90 degreesC, argon) to give as major product tris(4-methoxybenzyl)phosphine oxide in up to 45% yield. With white phosphorus at lower (70 degreesC) temperature this reaction yields mainly bis(4-methoxybenzyl)phosphine oxide. Phosphine reacts with 4-methoxybenzyl chloride in superbasic KOH-DMSO suspension, and under definite conditions bis(4-methoxybenzyl)phosphine oxide is predominantly formed.

  DOI：

  10.1023/a:1012377322193

文献信息

• Aminopeptidase A inhibitors and pharmaceutical compositions comprising the same
  申请人：QUANTUM GENOMICS

  公开号：US11192907B2

  公开（公告）日：2021-12-07

  The present invention relates to a novel compound, to a composition comprising the same, to methods for preparing the compound, and the use of this compound in therapy. In particular, the present invention relates to a compound that is useful in the treatment and prevention of primary and secondary arterial hypertension, ictus, myocardial ischaemia, cardiac and renal insufficiency, myocardial infarction, peripheral vascular disease, diabetic proteinuria, Syndrome X and glaucoma.

  本发明涉及一种新型化合物、一种包含该化合物的组合物、制备该化合物的方法以及该化合物在治疗中的应用。特别是，本发明涉及一种可用于治疗和预防原发性和继发性动脉高血压、心肌梗塞、心肌缺血、心肾功能不全、心肌梗塞、外周血管疾病、糖尿病蛋白尿、X综合征和青光眼的化合物。
• Synthesis of Monosubstituted Phosphinic Acids:  Palladium-Catalyzed Cross-Coupling Reactions of Anilinium Hypophosphite
  作者：Jean-Luc Montchamp、Yves R. Dumond

  DOI：10.1021/ja005721c

  日期：2001.1.1
• NANOCRYSTALS WITH FUNCTIONAL LIGANDS
  申请人：Tulsky Eric

  公开号：US20110256404A1

  公开（公告）日：2011-10-20

  Coated fluorescent semiconductor nanoparticles having an organic surface layer of multi-functional surface ligands that include a nanocrystal binding center and one or more covalently attached functional groups or reactive functional groups are described as well as water-dispersible nanoparticles having an organic surface layer or multi-functional surface ligands and methods for the preparation and use of such coated nanoparticles.
• AMINOPEPTIDASE A INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
  申请人：QUANTUM GENOMICS

  公开号：US20210309678A1

  公开（公告）日：2021-10-07

  The present invention relates to a novel compound, to a composition comprising the same, to methods for preparing the compound, and the use of this compound in therapy. In particular, the present invention relates to a compound that is useful in the treatment and prevention of primary and secondary arterial hypertension, ictus, myocardial ischaemia, cardiac and renal insufficiency, myocardial infarction, peripheral vascular disease, diabetic proteinuria, Syndrome X and glaucoma.
• US8901333B2
  申请人：——

  公开号：US8901333B2

  公开（公告）日：2014-12-02